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ABSTRACT
New genetic and environmental studies of Parkinson’s disease have revealed early 
problems in synaptic function and connectivity indicating that axonal impairment may 
be an important hallmark in this disorder. Since many studies suggest that axonal 
dysfunction precedes cell body loss, it is critical to target axons with treatments aimed 
at preserving “connectivity” as well as to develop and verify “biomarkers” with which to 
assess disease progression and drug efficacy.
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    Parkinson’s  disease  (PD)  is  a  common  neuro-
degenerative  disorder  with  at  least  one  million 
people  in  the  United  States  and  six  million  world-
wide  being  affected.  The  clinical  symptoms  of  PD, 
tremor,  rigidity  and  bradykinesia,  primarily  arise 
from  the  loss  of  dopaminergic  cells  in  the  sub-
stantia  nigra  pars  compacta.  Characteristic  path-
ological  changes  include  decreased  mitochondrial 
complex I activity and increased indices of oxidative 
stress  as  well  as  the  presence  of  intracellular  and 
axonal  deposits  called  Lewy  bodies  and  Lewy 
neurites,  respectively  (Samii  et  al.,  2004).  Although 
the  etiology  of  PD  remains  unknown,  both  genetic 
and  environmental  factors  appear  to  play  a  role. 
A  number  of  genes  associated  with  familial  PD 
have been identified (e.g. a-synuclein, parkin, DJ-1, 
PINK1,  LRRK2,  UCHL1,  ATP13A2)  demonstrating 
that molecular mechanisms underlying PD are com-
plex  and  likely  to  be  heterogeneous  (Schapira  et 
al.,  2009;  Westerlund  et  al.,  2010).  In  addition, 
exposure  to  toxins  such  as  N-methyl-4-phenyl- 
1,2,3,6-tetrahydropyridine  (MPTP)  or  its  active  de-
rivative,  MPP
＋,  results  in  a  disorder  that  mimics 
many  aspects  of  this  disease  (Westerlund  et  al., 
2010).
    Most knowledge about the molecular mechanisms 
underlying  PD  has  come  from  postmortem  tissue 
studies  as  well  as  the  genetic  associations  and 
environmental  toxins  which  mimic  the  disorder 
(Schapira  et  al.,  2009;  Westerlund  et  al.,  2010).  In 
general, these studies support the view that in PD, 
dopaminergic  neurons  die  via  programmed  cell 
death  or  apoptosis.  Thus  therapeutic  strategies 
aimed  at  halting  the  underlying  causes  of  cell  loss 
in  PD  have  targeted  apoptotic  pathways  with  some 
success,  at  least  in  animal  models.  Unfortunately, 
there is little clinical evidence to show that blocking 
cell  death  is  neuroprotective  (Waldmeier  et  al., 
2006).  These  results  underscore  the  need  for  bro-
adening  the  models  of  PD  pathogenesis.  Fur-
thermore,  it is  increasingly  apparent  that preserving 
critical  circuits  can  only  be  achieved  by  “staying 
connected”.   
    Recently,  ultrastructural,  physiological,  and  gene-
tic  studies  have  revealed  early  abnormalities  in 116 Karen  L.  O’Malley
Fig.  1.  Key  features  of  axonal  transport:  cargos,  tracks  and  motor  proteins.
synaptic  function  and  connectivity  in  PD.  Thus, 
mounting evidence indicates that axonal dysfunction 
may  be  an  important  hallmark  in  PD,  one  that 
unifies  the  many  disparate  models  (Hilliard,  2009; 
Morfini  et  al.,  2009). 
    How does impaired axonal transport lead to axon 
pathology?  Neurons  are  the  most  highly  polarized 
of  vertebrate  cells  with  axons  extending  up  to 
10,000  times  the  width  of  their  cell  bodies.  Thus, 
neurons depend upon efficient transport systems to 
get  “cargos”  (proteins,  vesicles,  and  other  organe-
lles)  where  they  need  to  go.  Cargos  move  along 
tracks  of  microtubules  with  the  help  of  specialized 
proteins. For instance, cargos are transported in the 
anterograde  direction  by  kinesin  motor  proteins 
while  cargos  returning  to  the  cell  body  are  largely 
transported  by  dynein  motors  (Cai  and  Sheng, 
2009).  When  either  process  is  disrupted,  cargos 
can  accumulate  leading  to  protein  aggregation,  the 
sequestration  of  cellular  factors  and  organelles, 
activation  of  cell  stress  signaling  cascades,  dis-
ruption  of  the  tracks  themselves  and  ultimately, 
axonal  degeneration.  Defective  axonal  transport  will 
also  lead  to  the  loss  of  new  material  and/or 
vesicles  at  the  distal  axon,  the  loss  of  neurotropic 
signaling,  the  failure  to  degrade  defective  proteins 
and  potentially  the  activation  of  programmed  cell 
death  pathways.  Finally,  even  very  subtle  changes 
in  axon  transport  may  lead  to  the  re-distribution  of 
important  organelles  such  as  mitochondria  with  an 
ensuing loss  of energy and consequently  disruption 
of  energy-driven  processes  such  as  synaptic  func-
tion,  movement  of  other  cargoes,  etc.  (Cai  and 
Sheng,  2009).  A  model  of  some  of  these  key 
features  is  shown  in  Fig.  1.   
    What  is  the  evidence  that  defective  axonal 
transport  plays  a  role  in  PD?  First,  there  is 
widespread  axonal  pathology  from  the  earliest 
stages  of  the  disorder  suggesting  that  axonal 
function  is  impaired  (Braak  et  al.,  2004).  Moreover, 
in  patient,  non-human  primate  and  animal  models 
of  PD,  the  loss  of  axons  appears  to  precede  the 
loss  of  cell  bodies  (Dauer  and  Przedborski,  2003). 
For  example,  the  onset  of  symptoms  in  patients 
appears  after  most  of  the  axonal  dopamine  in  the 
striatum  has  been  depleted  (70∼80%)  and  about 
half  of  the  nigral  dopamine-producing  cells  have 
died  (Bernheimer  et  al.,  1973).  Also,  the  appear-
ance  of  α-synuclein-positive  Lewy  neurites  almost 
always precedes that of Lewy Bodies (Braak et al., 
2004; Orimo et al., 2008). These observations have 
led  to  the  hypothesis  that  nigral  neurons  de-
generate  through  a  “dying  back”  axonopathy  in 
which  degeneration  begins  in  the  distal  axon  and 
proceeds  over  weeks  or  months  towards  the  cell 
body  (Raff  et  al.,  2002).
    Second,  mutations  in  the  PD-linked  Leucine-Rich 
Repeat  Kinase  2  (LRRK2)  gene,  which  represent 
the  most  common  genetic  cause  for  familial  (6%) 
and  idiopathic  (1∼2%)  PD  is  also  associated  with 
aggregated  axonal  α-synuclein  as  well  as  with  tau 
pathology  (Ballatore  et  al.,  2007).  Knockdown  of 
LRRK2  or  introduction  of  “kinase-dead”  constructs 
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whereas  constructs  with  increased  kinase  activity 
exhibit  very  short  simple  processes  in  neuronal 
cultures  or  transduced  nigrostriatal  models  (Mac-
Leod  et  al.,  2006).  Moreover,  transgenic  mice  ex-
pressing  the  PD-linked  mutation  LRRK2  (R1441G) 
recapitulate  key  features  of  PD  itself  including 
motoric, neurochemical and pathological features (Li 
et  al.,  2009).  Importantly,  these  animals  exhibit  an 
early,  progressive  decline  in  dopaminergic  terminal 
fields with a more than 8-fold increase in dystrophic 
processes and abnormal axonal swellings (Li et al., 
2009).  Thus,  these  data  also  support  the  idea  that 
impaired  axonal  transport  plays  an  early,  pivotal 
role  in  LRRK2-associated  PD. 
  T h i r d ,  α-synuclein-positive Lewy neurites precede 
Lewy  bodies  in  the  brain  (Braak  et  al.,  2004)  as 
well  as  in  the  cardiac  sympathetic  nervous  system 
(Orimo  et  al.,  2008).  Specifically  α-synuclein  ag-
gregates  appear  first  in  distal  axons  then  as  these 
regress,  aggregates  accumulate  in  more  proximal 
axons  and  subsequently  cell  bodies  (Braak  et  al., 
2004;  Orimo  et  al.,  2008).  Conceivably,  this  early 
chronology  mirrors  the  pathological  mechanism 
associated  with  PD.  Additionally,  α-synuclein  mu-
tants.  accumulate  in  the  cell  soma  when  over-
expressed  in  cortical  neurons,  suggesting  reduced 
axonal transport as well (Saha et al., 2004). Recent 
studies  examining  protein  domains  associated  with 
transport  indicate  that  those  regions  involved  in 
membrane  binding  decreased  the  number  of  α
-synuclein  particles  present  in  hippocampal  sy-
napses  (Yang  et  al.,  2010).  Authors  speculate  that 
α-synuclein  might  function  as  a  scaffolding  protein 
linking  membranous  cargoes  with  microtubule-de-
pendent  axonal  transport  (Yang  et  al.,  2010) 
    Fourth, genetic mutations in the PD-linked genes, 
Parkin,  an  E3  ligase,  and  PINK1  (PTEN-induced 
putative kinase 1 protein) a mitochondrially-targeted 
kinase,  have  been  shown  to  regulate  mitochondrial 
fission/fusion  machinery  and  alter  axonal  transport 
(Lu,  2009;  Bueler,  2010).  For  example,  mitochon-
dria are not only transported up and down the axon 
they  also  undergo  dynamic  interconversion  events 
in  which  two  mitochondria  fuse  to  form  a  long 
tubular  structure  (fusion)  or  a  single  mitochondria 
splits  in  two  (fission).  Fusion/fission  processes  are 
thought  to  be  intimately  involved  in  mitochondrial 
transport since 1) mutations associated with Drp1, a 
fusion  promoting  gene,  impair  axonal  transport  (Lu, 
2009);  2)  fused,  elongated  mitochondria  are  less 
mobile  then  short,  vesicular  structures  (Cai  and 
Sheng,  2009);  and  3)  fission  generates  healthy 
mitochondria  that  are  transported  down  the  axon 
whereas  damaged,  dysfunctional  mitochondria  are 
sent  back  to  the  cell  body  for  repair  by  fusion  or 
degraded  via  mitophagy  (Miller  and  Sheetz,  2005). 
Very recent data  indicate that PINK 1  is selectively 
stabilized  on  depolarized  mitochondrial  membranes. 
This  in  turn  acts  as  a  signal  for  Parkin  recruitment 
which  tags  Pink-positive,  depolarized  mitochondria 
for  destruction  via  autophagy  (i.e.  mitophagy;  Na-
rendra  et  al.,  2010).  PINK1  can  also  form  a 
complex  with  the  key  mitochondrial  transport 
proteins,  Miro  and  Milton  (Weihofen  et  al.,  2009). 
Taken  together  these  data  suggest  that  PINK1/ 
Parkin  PD-linked  mutations  lead  to  impaired  mito-
chondrial  dynamics  resulting  in  altered  transport, 
distribution  and  loss  of  synaptic  function.   
    Fifth,  environmental  toxins  known  to  mimic  PD 
such  as  rotenone  and  MPTP  or  MPP
＋,  not  only 
inhibit mitochondrial Complex I activity, but also de- 
polymerize  microtubules  which  take  on  a  beaded, 
broken  appearance  leading  to  axon  fragmentation 
(Cappelletti  et  al.,  2005;  Ren  et  al.,  2005).  This 
might  be  due  to  a  direct  interaction  or  indirectly  as 
a  consequence  of  Complex  I  inhibition  resulting  in 
the  loss  of  ATP  and  increased  oxidative  stress 
(Cappelletti et al., 2005; Ren et al., 2005). In either 
case, loss of microtubule integrity would clearly lead 
to  axonal  degeneration  (Fig.  1). 
    Sixth,  recent  data  suggest  that  the  Wallerian 
degeneration  slow  fusion  protein  (Wld
S)  can  delay 
axonal  degeneration  about  10-fold  from  a  wide 
variety  of  genetic  and  toxin-inducing  stimuli  in  vivo 
and in vitro. Wld
S is a chimeric protein composed of 
the  N-terminal  70  amino  acids  of  the  ubiquitination 
factor  Ube4b  followed  by  a  18  amino  acid  linker 
region  and  the  entire  sequence  of  Nmnat1,  a  key 
enzyme  in  the  biosynthesis  of  NAD
＋  (Mack  et  al., 
2001).  Most  studies suggest  that  catalytically active 
Nmnat1 is necessary for axonal protection although 
it is unclear whether increased NAD
＋ is responsible 
(Sasaki  et  al.,  2009).  Despite  Wld
S  being  primarily 
localized  in  the  nucleus,  subcellular  localization 
studies  have  found  substantial  amounts  of  Wld
S 
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hance ATP synthesis (Yahata et al., 2009), prevent 
free  radical  formation  (Press  and  Milbrandt,  2009), 
or  maintain  mitochondrial  membrane  potential  (Ike-
gami  and  Koike,  2003).  Data  from  this  lab  has 
shown  that  in  the  mouse  MPTP  model,  the  Wld
S 
gene  product  enhances  survival,  prevents  nigro-
striatal  axon  degeneration,  and  attenuates  neuro-
transmitter  loss  but  does  not  rescue  cell  bodies 
(Hasbani  and  O’Malley,  2006).  Despite  this  striking 
terminal  field  preservation,  how  Wld
S  prevents 
axonal  dysfunction  is  unknown  but  may  be  related 
to  its  effects  on  mitochondrial  function. 
    Finally  results  using  the  isolated  squid  axoplasm 
model support the notion that MPP
＋ directly inhibits 
fast  axonal  transport  independent  of  mitochondria 
effects  (Morfini  et  al.,  2009).  Specifically,  MPP
＋ 
increases  retrograde  trafficking  of  organelles  in  a 
PKCδ,  caspase  3-dependent  process.  This  in  turn 
leads  to  a  loss  of  appropriate  neurotransmission 
and  failure  to  generate  post  synaptic  responses 
(Morfini  et  al.,  2009).  Taken  together,  these  data 
provide direct  evidence that  the  PD-mimetic,  MPP
＋ 
rapidly  affects  critical  axonal  processes.  Moreover, 
using  compartmented  chambers  and  dopaminergic 
neurons  derived  from  genetically  altered  animals 
expressing  targeted  GFP,  we  have  been  able  to 
show  that,  like  the  squid  giant  axon,  MPP
＋  affects 
axonal  trafficking  (Unpublished  results). 
    Taken  together,  results  from  both  environmental 
and  genetic  factors  linked  to  PD  support  an  early, 
critical  role  for  axonal  impairment  in  this  disorder. 
Therefore, it is critical to target new drugs to axons 
in order to preserve “connectivity”. At the very least, 
efforts  to  delay  axonal  dysfunction  may  push  back 
the  disease  clock  allowing  those  afflicted  to  main-
tain  an  improved  quality  of  life.  Ultimately,  thera-
peutics targeted towards both the axon and the cell 
body may provide the most efficacious treatment of 
all.
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